Gregory Renza
Stock Analyst at RBC Capital
(3.42)
# 976
Out of 5,043 analysts
221
Total ratings
40.31%
Success rate
6.64%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Outperform | $31 → $35 | $99.98 | -64.99% | 3 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Outperform | $26 | $22.99 | +13.09% | 16 | May 19, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Outperform | $8 | $4.29 | +86.48% | 12 | May 15, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Sector Perform | $5 | $2.49 | +100.80% | 11 | May 14, 2025 | |
| EXEL Exelixis | Reiterates: Outperform | $40 | $39.99 | +0.03% | 10 | May 14, 2025 | |
| ONC BeOne Medicines AG | Maintains: Outperform | $312 → $311 | $315.43 | -1.40% | 2 | May 8, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $182 → $172 | $139.33 | +23.45% | 14 | May 7, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $35 → $32 | $8.12 | +294.09% | 3 | May 2, 2025 | |
| AMGN Amgen | Maintains: Outperform | $324 → $320 | $291.16 | +9.91% | 17 | May 2, 2025 | |
| CGON CG Oncology | Maintains: Outperform | $66 → $68 | $44.29 | +53.53% | 3 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $113 → $38 | $123.02 | -69.52% | 14 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $15 | $3.10 | +383.87% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $11.05 | +8.60% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $8.72 | +60.55% | 10 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $32 | $14.27 | +124.25% | 9 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $27 | $11.98 | +125.38% | 11 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $32.37 | +88.45% | 12 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $21.33 | -15.61% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $2.33 | +1,960.09% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 → $10 | $5.04 | +98.41% | 6 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $7 → $10 | $5.42 | +84.50% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $22.54 | +108.52% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $57 | $43.08 | +32.31% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $9.65 | -58.55% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $110 → $20 | $3.76 | +431.91% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $0.97 | +1,544.06% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $17.99 | +900.56% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $1.34 | +5,870.15% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $0.68 | +4,328.04% | 3 | Jun 2, 2020 |
Cidara Therapeutics
May 23, 2025
Maintains: Outperform
Price Target: $31 → $35
Current: $99.98
Upside: -64.99%
ACADIA Pharmaceuticals
May 19, 2025
Reiterates: Outperform
Price Target: $26
Current: $22.99
Upside: +13.09%
ADC Therapeutics
May 15, 2025
Reiterates: Outperform
Price Target: $8
Current: $4.29
Upside: +86.48%
Inovio Pharmaceuticals
May 14, 2025
Reiterates: Sector Perform
Price Target: $5
Current: $2.49
Upside: +100.80%
Exelixis
May 14, 2025
Reiterates: Outperform
Price Target: $40
Current: $39.99
Upside: +0.03%
BeOne Medicines AG
May 8, 2025
Maintains: Outperform
Price Target: $312 → $311
Current: $315.43
Upside: -1.40%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $182 → $172
Current: $139.33
Upside: +23.45%
Bicycle Therapeutics
May 2, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $8.12
Upside: +294.09%
Amgen
May 2, 2025
Maintains: Outperform
Price Target: $324 → $320
Current: $291.16
Upside: +9.91%
CG Oncology
Apr 29, 2025
Maintains: Outperform
Price Target: $66 → $68
Current: $44.29
Upside: +53.53%
Apr 16, 2025
Maintains: Sector Perform
Price Target: $113 → $38
Current: $123.02
Upside: -69.52%
Mar 27, 2025
Maintains: Outperform
Price Target: $16 → $15
Current: $3.10
Upside: +383.87%
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $11.05
Upside: +8.60%
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $8.72
Upside: +60.55%
Feb 27, 2025
Maintains: Outperform
Price Target: $34 → $32
Current: $14.27
Upside: +124.25%
Jan 29, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $11.98
Upside: +125.38%
Jan 15, 2025
Reiterates: Outperform
Price Target: $61
Current: $32.37
Upside: +88.45%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $21.33
Upside: -15.61%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $2.33
Upside: +1,960.09%
Jan 7, 2025
Reiterates: Outperform
Price Target: $6 → $10
Current: $5.04
Upside: +98.41%
Dec 19, 2024
Upgrades: Outperform
Price Target: $7 → $10
Current: $5.42
Upside: +84.50%
Dec 17, 2024
Maintains: Outperform
Price Target: $44 → $47
Current: $22.54
Upside: +108.52%
Dec 10, 2024
Maintains: Outperform
Price Target: $55 → $57
Current: $43.08
Upside: +32.31%
Nov 14, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $9.65
Upside: -58.55%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $110 → $20
Current: $3.76
Upside: +431.91%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $0.97
Upside: +1,544.06%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $17.99
Upside: +900.56%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $1.34
Upside: +5,870.15%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $0.68
Upside: +4,328.04%